196 related articles for article (PubMed ID: 20562921)
21. Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.
Győrffy B; Stelniec-Klotz I; Sigler C; Kasack K; Redmer T; Qian Y; Schäfer R
Oncotarget; 2015 May; 6(15):13334-46. PubMed ID: 26033452
[TBL] [Abstract][Full Text] [Related]
22. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
23. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
[TBL] [Abstract][Full Text] [Related]
24. Ral GTPases in tumorigenesis: emerging from the shadows.
Kashatus DF
Exp Cell Res; 2013 Sep; 319(15):2337-42. PubMed ID: 23830877
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
26. Activation and involvement of Ral GTPases in colorectal cancer.
Martin TD; Samuel JC; Routh ED; Der CJ; Yeh JJ
Cancer Res; 2011 Jan; 71(1):206-15. PubMed ID: 21199803
[TBL] [Abstract][Full Text] [Related]
27. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
28. Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
Pomeroy EJ; Eckfeldt CE
Small GTPases; 2020 Jan; 11(1):39-44. PubMed ID: 28682649
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
30. Ral GTPase Activation by Downregulation of RalGAP Enhances Oral Squamous Cell Carcinoma Progression.
Gao P; Liu S; Yoshida R; Shi CY; Yoshimachi S; Sakata N; Goto K; Kimura T; Shirakawa R; Nakayama H; Sakata J; Kawashiri S; Kato K; Wang XY; Horiuchi H
J Dent Res; 2019 Aug; 98(9):1011-1019. PubMed ID: 31329042
[TBL] [Abstract][Full Text] [Related]
31. The RAL Enigma: Distinct Roles of RALA and RALB in Cancer.
Richardson DS; Spehar JM; Han DT; Chakravarthy PA; Sizemore ST
Cells; 2022 May; 11(10):. PubMed ID: 35626682
[TBL] [Abstract][Full Text] [Related]
32. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
33. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.
Gentry LR; Nishimura A; Cox AD; Martin TD; Tsygankov D; Nishida M; Elston TC; Der CJ
J Biol Chem; 2015 Sep; 290(37):22851-61. PubMed ID: 26216878
[TBL] [Abstract][Full Text] [Related]
34. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
[TBL] [Abstract][Full Text] [Related]
35. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.
Greshock J; Nathanson K; Medina A; Ward MR; Herlyn M; Weber BL; Zaks TZ
Genes Chromosomes Cancer; 2009 May; 48(5):419-28. PubMed ID: 19226609
[TBL] [Abstract][Full Text] [Related]
36. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
37. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
Yan C; Theodorescu D
Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
[TBL] [Abstract][Full Text] [Related]
38. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
39. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
40. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
